

# Karl-Erik Andersson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007079/publications.pdf>

Version: 2024-02-01

135  
papers

4,304  
citations

136950

32  
h-index

118850

62  
g-index

138  
all docs

138  
docs citations

138  
times ranked

3804  
citing authors

#	ARTICLE	IF	CITATIONS
1	Re: Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years. <i>European Urology</i> , 2021, 79, 431-432.	1.9	1
2	Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3981.	4.1	14
3	Gene Therapy for Overactive Bladder: A Review of BK-Channel $\alpha$ -Subunit Gene Transfer. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 589-599.	2.0	11
4	Are there relevant animal models to set research priorities in LUTD? ICIERS 2019. <i>Neurourology and Urodynamics</i> , 2020, 39, S9-S15.	1.5	2
5	Gene Therapy in Erectile Dysfunction: Dead or Alive?. <i>Journal of Sexual Medicine</i> , 2020, 17, 1587-1589.	0.6	3
6	Best practices for cystometric evaluation of lower urinary tract function in muriform rodents. <i>Neurourology and Urodynamics</i> , 2020, 39, 1868-1884.	1.5	22
7	Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICIERS 2019. <i>Neurourology and Urodynamics</i> , 2020, 39, S16-S22.	1.5	21
8	Inside Front Cover Image, Volume 39, Number 2, February 2020. <i>Neurourology and Urodynamics</i> , 2020, 39, ii.	1.5	0
9	Evaluating the safety and potential activity of UROa902 (hMaxiaEK) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. <i>Neurourology and Urodynamics</i> , 2020, 39, 744-753.	1.5	25
10	Incontinence in Patients With Underactive Bladder. <i>International Neurourology Journal</i> , 2020, 24, 293-294.	1.2	1
11	The serotonin (5-hydroxytryptamine) 5-HT <sub>7</sub> receptor is upregulated in Onuf's nucleus in rats with chronic spinal cord injury. <i>BJU International</i> , 2019, 123, 718-725.	2.5	11
12	Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. <i>BJU International</i> , 2019, 123, 995-1004.	2.5	13
13	Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 749-755.	4.1	21
14	Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. <i>World Journal of Urology</i> , 2019, 37, 2199-2205.	2.2	4
15	Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. <i>Pharmaceutical Research</i> , 2019, 36, 92.	3.5	7
16	TRP Channels as Lower Urinary Tract Sensory Targets. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 67.	2.9	25
17	Oxidative stress and lower urinary tract symptoms: cause or consequence?. <i>BJU International</i> , 2019, 123, 749-750.	2.5	6
18	Streptozotocin-induced diabetes causes upregulation of serotonin (5-HT) <sub>2A/C</sub> receptors in lumbosacral cord motoneurons and down regulation of serotonergic paraneurons in the urethra. <i>Brain Research</i> , 2019, 1715, 21-26.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. <i>European Urology</i> , 2019, 75, 129-168.	1.9	19
20	Future Considerations in Overactive Bladder Pharmacotherapy. , 2019, , 219-229.		1
21	Current concepts of the acontractile bladder. <i>BJU International</i> , 2018, 122, 195-202.	2.5	7
22	Chronic spinal cord injury causes upregulation of serotonin (5-HT <sub>2A</sub> ) and 5-HT <sub>2C</sub> receptors in lumbosacral cord motoneurons. <i>BJU International</i> , 2018, 121, 145-154.	2.5	7
23	Oxidative stress and its possible relation to lower urinary tract functional pathology. <i>BJU International</i> , 2018, 121, 527-533.	2.5	33
24	Development of contractile properties in the fetal porcine urinary bladder. <i>Pediatric Research</i> , 2018, 83, 148-155.	2.3	1
25	Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 570-578.	3.9	10
26	Nonhuman primate model of persistent erectile and urinary dysfunction following radical prostatectomy: Feasibility of minimally invasive therapy. <i>Neurourology and Urodynamics</i> , 2018, 37, 2141-2150.	1.5	11
27	Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction. <i>Neurourology and Urodynamics</i> , 2018, 37, 2414-2424.	1.5	5
28	Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. <i>International Neurourology Journal</i> , 2018, 22, S3-9.	1.2	56
29	The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. <i>Therapeutic Advances in Urology</i> , 2018, 10, 243-256.	2.0	9
30	Neuroepithelial control of mucosal inflammation in acute cystitis. <i>Scientific Reports</i> , 2018, 8, 11015.	3.3	22
31	Which molecular targets do we need to focus on to improve lower urinary tract dysfunction? ICIâ€RS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S117-S126.	1.5	15
32	Fibrosis and the bladder, implications for function ICIâ€RS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S7-S12.	1.5	36
33	Cell Versus Chemokine Therapy Effects on Cell Mobilization to Chronically Dysfunctional Urinary Sphincters of Nonhuman Primates. <i>International Neurourology Journal</i> , 2018, 22, 260-267.	1.2	4
34	Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 369-375.	0.4	39
35	Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. <i>Pain</i> , 2017, 158, 1538-1545.	4.2	17
36	Can incontinence be cured? A systematic review of cure rates. <i>BMC Medicine</i> , 2017, 15, 63.	5.5	68

#	ARTICLE	IF	CITATIONS
37	Efficacy and Initial Safety Profile of CXCL12 Treatment in a Rodent Model of Urinary Sphincter Deficiency. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1740-1746.	3.3	10
38	Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. <i>Scientific Reports</i> , 2017, 7, 7646.	3.3	17
39	Evaluating the Procedure for Performing Awake Cystometry in a Mouse Model. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	6
40	Re: Inhibition of Cholinergic Neurotransmission by $\hat{I}^2$ 3 -adrenoceptors Depends on Adenosine Release and A 1 Receptors Activation in Human and Rat Urinary Bladders. <i>European Urology</i> , 2017, 72, 650-651.	1.9	0
41	Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. <i>Stem Cell Research and Therapy</i> , 2017, 8, 1.	5.5	138
42	Erectile Dysfunction and Lower Urinary Tract Symptoms. <i>European Urology Focus</i> , 2017, 3, 352-363.	3.1	68
43	Regenerative pharmacology in urology. <i>Investigative and Clinical Urology</i> , 2017, 58, 79.	2.0	1
44	Drugs for the overactive bladder: are there differences in persistence and compliance?. <i>Translational Andrology and Urology</i> , 2017, 6, 597-601.	1.4	7
45	Current Pharmacologic Approaches in Painful Bladder Research: An Update. <i>International Neurourology Journal</i> , 2017, 21, 235-242.	1.2	21
46	Association of lower urinary tract syndrome with peripheral arterial occlusive disease. <i>PLoS ONE</i> , 2017, 12, e0170288.	2.5	19
47	On the Site and Mechanism of Action of $\hat{I}^{23}$ -Adrenoceptor Agonists in the Bladder. <i>International Neurourology Journal</i> , 2017, 21, 6-11.	1.2	43
48	Characterization of a Murine Model of Bioequivalent Bladder Wound Healing and Repair Following Subtotal Cystectomy. <i>BioResearch Open Access</i> , 2017, 6, 35-45.	2.6	1
49	Regenerative pharmacology: recent developments and future perspectives. <i>Regenerative Medicine</i> , 2016, 11, 859-870.	1.7	9
50	Melatonin Improves Erectile Function in Rats with Chronic Lower Body Ischemia. <i>Journal of Sexual Medicine</i> , 2016, 13, 179-186.	0.6	6
51	Cell versus Chemokine Therapy in a Nonhuman Primate Model of Chronic Intrinsic Urinary Sphincter Deficiency. <i>Journal of Urology</i> , 2016, 196, 1809-1815.	0.4	19
52	Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunctionâ€”IClâ€RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 318-323.	1.5	21
53	Potential Future Pharmacological Treatment of Bladder Dysfunction. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 75-85.	2.5	61
54	Regenerative Medicine Therapies for Stress Urinary Incontinence. <i>Journal of Urology</i> , 2016, 196, 1619-1626.	0.4	27

#	ARTICLE	IF	CITATIONS
55	Re: Nonantimuscarinic Treatment for Overactive Bladder: A Systematic Review. <i>European Urology</i> , 2016, 70, 1077.	1.9	0
56	Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency. <i>Stem Cell Research and Therapy</i> , 2016, 7, 147.	5.5	14
57	Preventive Effects of Long-Term Caloric Restriction on Aging Related In Vivo Bladder Dysfunction and Molecular Biological Changes in the Bladder and Dorsal Root Ganglia in Rats. <i>Journal of Urology</i> , 2016, 196, 1575-1583.	0.4	13
58	Sensitivity to the thromboxane A <sub>2</sub> analog U46619 varies with inner diameter in human stem villous arteries. <i>Placenta</i> , 2016, 39, 111-115.	1.5	4
59	Tramadol Abuse and Sexual Function. <i>Sexual Medicine Reviews</i> , 2016, 4, 235-246.	2.9	39
60	On the mode of action of mirabegron. <i>Nature Reviews Urology</i> , 2016, 13, 131-132.	3.8	11
61	The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). <i>BMC Urology</i> , 2015, 15, 103.	1.4	1
62	Serotonin (5-HT) <sub>2A/2C</sub> receptor agonist (2,5-dimethoxy-4-(2-dimethylamino)phenyl)ethanamine hydrochloride (DOI) improves voiding efficiency in the diabetic rat. <i>BJU International</i> , 2015, 116, 147-155.	2.3	10
63	Drug therapy of overactive bladder - What is coming next?. <i>Korean Journal of Urology</i> , 2015, 56, 673.	1.2	7
64	Superoxide overproduction and kidney fibrosis: a new animal model. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 79-88.	0.7	10
65	Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (<sc>LUTS</sc>): A New Target for Pharmacological Treatment?. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 1-8.	1.3	32
66	Translational Research and Functional Changes in Voiding Function in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 535-548.	2.6	19
67	Differentiated adipose-derived stem cells for bladder bioengineering. <i>Scandinavian Journal of Urology</i> , 2015, 49, 407-414.	1.0	14
68	Potential of stem cell treatment in detrusor dysfunction. <i>Advanced Drug Delivery Reviews</i> , 2015, 82-83, 117-122.	13.7	7
69	Intraprostatic injections for lower urinary tract symptoms treatment. <i>Current Opinion in Urology</i> , 2015, 25, 12-18.	1.8	10
70	Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients. <i>Genomics Data</i> , 2014, 2, 366-368.	1.3	2
71	Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F823-F832.	2.7	25
72	The use of pharmacotherapy for male patients with urgency and stress incontinence. <i>Current Opinion in Urology</i> , 2014, 24, 571-577.	1.8	8

#	ARTICLE	IF	CITATIONS
73	The many faces of impaired bladder emptying. <i>Current Opinion in Urology</i> , 2014, 24, 363-369.	1.8	32
74	Progressive Vascular Damage May Lead to Bladder Underactivity in Rats. <i>Journal of Urology</i> , 2014, 191, 1462-1469.	0.4	61
75	Lamina propria: The functional center of the bladder?. <i>Neurourology and Urodynamics</i> , 2014, 33, 9-16.	1.5	123
76	Effects of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy on Voiding Function in a Rat Model of Parkinson Disease. <i>Journal of Urology</i> , 2014, 191, 850-859.	0.4	20
77	Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. <i>Nature Reviews Urology</i> , 2014, 11, 555-564.	3.8	38
78	Bladder Underactivity. <i>European Urology</i> , 2014, 65, 399-401.	1.9	22
79	Correlation of Gene Expression with Bladder Capacity in Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2014, 192, 1123-1129.	0.4	46
80	β <sub>3</sub> -Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?. <i>Current Urology Reports</i> , 2013, 14, 435-441.	2.2	11
81	Treatment of lower urinary tract symptoms: Agents for intraprostatic injection. <i>Scandinavian Journal of Urology</i> , 2013, 47, 83-90.	1.0	15
82	Age-Related Alterations in Regeneration of the Urinary Bladder after Subtotal Cystectomy. <i>American Journal of Pathology</i> , 2013, 183, 1585-1595.	3.8	10
83	The novel β <sub>3</sub> -adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. <i>European Journal of Pharmacology</i> , 2013, 699, 101-105.	3.5	41
84	Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. <i>International Journal of Urology</i> , 2013, 20, 21-27.	1.0	30
85	Selective β <sub>3</sub> -Adrenoceptor Agonists for the Treatment of Overactive Bladder. <i>Journal of Urology</i> , 2013, 190, 1173-1180.	0.4	63
86	Future therapies: Early trials and basic science. <i>Canadian Urological Association Journal</i> , 2013, 7, 179.	0.6	0
87	Animal Models of Regenerative Medicine. , 2013, , 219-234.		1
88	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 161.	2.0	44
89	Stem and Progenitor Cells in Regenerative Pharmacology. , 2013, , 75-126.		3
90	Introduction to Regenerative Pharmacology: A Short Primer on the Role of Pharmacological Sciences in Regenerative Medicine. , 2013, , 3-14.		1

#	ARTICLE	IF	CITATIONS
91	Therapeutic targets for premature ejaculation. <i>Maturitas</i> , 2011, 70, 26-33.	2.4	16
92	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 186-196.	2.4	56
93	Antimuscarinic Mechanisms and the Overactive Detrusor: An Update. <i>European Urology</i> , 2011, 59, 377-386.	1.9	138
94	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. <i>Neurourology and Urodynamics</i> , 2011, 30, 292-301.	1.5	185
95	Rodent models for urodynamic investigation. <i>Neurourology and Urodynamics</i> , 2011, 30, 636-646.	1.5	166
96	Drugs and future candidates. <i>Canadian Urological Association Journal</i> , 2011, 5, S131-s133.	0.6	9
97	Studies of age-related impairments in regenerative capacity in adult mammals using the rodent bladder. <i>FASEB Journal</i> , 2011, 25, 1087.13.	0.5	0
98	Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. <i>Cell and Tissue Research</i> , 2010, 342, 295-306.	2.9	62
99	Re: Spontaneous Release of Acetylcholine from Autonomic Nerves in the Bladder. <i>European Urology</i> , 2010, 57, 171-172.	1.9	2
100	Detrusor myocyte activity and afferent signaling. <i>Neurourology and Urodynamics</i> , 2010, 29, 97-106.	1.5	89
101	The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. <i>BJU International</i> , 2010, 106, 1114-1127.	2.5	95
102	Maturation and growth of the bladder wall in a rodent model of organ regeneration. <i>FASEB Journal</i> , 2010, 24, 754.1.	0.5	0
103	Prospective pharmacologic therapies for the overactive bladder. <i>Therapeutic Advances in Urology</i> , 2009, 1, 71-83.	2.0	37
104	The evolving physiology of the lower urinary tract: What we are learning and where we need to go. <i>Current Bladder Dysfunction Reports</i> , 2009, 4, 81-85.	0.5	0
105	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009, 19, 380-394.	1.8	161
106	Studies of tissue regeneration in a rat bladder model in vivo. <i>FASEB Journal</i> , 2009, 23, 939.1.	0.5	0
107	Pharmacotherapy of the overactive bladder. <i>Discovery Medicine</i> , 2009, 8, 118-24.	0.5	26
108	Urothelial effects of oral agents for overactive bladder. <i>Current Urology Reports</i> , 2008, 9, 459-464.	2.2	21

#	ARTICLE	IF	CITATIONS
109	Are female lower urinary tract symptoms alleviated by $\alpha_1$ -adrenoreceptor antagonists?. <i>Nature Reviews Urology</i> , 2008, 5, 586-587.	1.4	1
110	Pharmacology of $\alpha_1$ -adrenoreceptor antagonists in the lower urinary tract and central nervous system. <i>Nature Reviews Urology</i> , 2007, 4, 368-378.	1.4	123
111	What's hot from the ICS Annual Meeting 2006. <i>Neurourology and Urodynamics</i> , 2007, 26, 148-153.	1.5	0
112	Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. <i>Neurourology and Urodynamics</i> , 2007, 26, 928-933.	1.5	71
113	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. <i>BJU International</i> , 2007, 100, 1007-1014.	2.5	27
114	REGENERATIVE PHARMACOLOGY: THE FUTURE IS NOW. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2007, 7, 79-86.	3.4	18
115	Voiding patterns in uroplakin II knockout mice. <i>FASEB Journal</i> , 2007, 21, A1301.	0.5	0
116	URODYNAMIC CHARACTERIZATION OF MICE LACKING UROPLAKIN II OR III. <i>FASEB Journal</i> , 2007, 21, A1308.	0.5	2
117	Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin (STZ)-diabetic rats. <i>FASEB Journal</i> , 2007, 21, A420.	0.5	0
118	Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology. <i>Physiological Reviews</i> , 2004, 84, 935-986.	28.8	766
119	Inhibitory Effects of Nitrendipine on Myometrial and Vascular Smooth Muscle in Human Pregnant Uterus and Placenta. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 59, 1-10.	0.0	51
120	Direct Effects of Adenosine and Adenine Nucleotides on Isolated Human Urinary Bladder and their Influence on Electrically Induced Contractions. <i>Journal of Urology</i> , 1983, 130, 392-398.	0.4	74
121	Atropine Resistance of Transmurally Stimulated Isolated Human Bladder Muscle. <i>Journal of Urology</i> , 1982, 128, 1368-1371.	0.4	256
122	Multichannel intrauterine pressure recording by means of microtransducers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1979, 58, 115-120.	2.8	29
123	Uterine Activity in Diabetes Insipidus. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1977, 56, 381-385.	2.8	6
124	Kidney and Bladder Regeneration: Pharmacologic Methods. , 0, , 52-72.		0
125	Micro- and Nanoscale Delivery of Therapeutic Agents for Regenerative Therapy. , 0, , 127-156.		0
126	Mechanical Control of Adult Mesenchymal Stem Cells in Cardiac Applications. , 0, , 34-51.		0



#	ARTICLE	IF	CITATIONS
127	The Past, Present, and Future of Tissue Regeneration. , 0, , 311-328.		0
128	Incorporation of Active Factors (Pharmacological Substances) in Biomaterials for Tissue Engineering. , 0, , 167-189.		0
129	Gap Junctionâ€“Mediated Therapies to Eliminate Cardiac Arrhythmias. , 0, , 237-251.		1
130	Regenerative Pharmacology of the Bladder. , 0, , 15-33.		1
131	Bioreactor Technologies for Tissue Engineering a Replacement Heart Valve. , 0, , 157-166.		0
132	Enabling Drug Discovery Technologies for Regenerative Pharmacology. , 0, , 190-218.		0
133	Regenerative Cardiac Pharmacology: Translating Stem Cell Biology into Therapeutic Solutions. , 0, , 252-269.		0
134	Wound Healing and Cell Therapy for Muscle Repair. , 0, , 270-289.		0
135	Regenerative Pharmacology of Implanted Materials and Tissue-Engineered Constructs. , 0, , 290-310.		0